An updated review of the molecular mechanisms in drug hypersensitivity

CB Chen, R Abe, RY Pan, CW Wang… - Journal of …, 2018 - Wiley Online Library
Drug hypersensitivity may manifest ranging from milder skin reactions (eg, maculopapular
exanthema and urticaria) to severe systemic reactions, such as anaphylaxis, drug reactions …

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to …

D Khanna, JD Fitzgerald, PP Khanna… - Arthritis care & …, 2012 - Wiley Online Library
Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a
foundation of an excess body burden of uric acid, manifested in part by hyperuricemia …

HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

SI Hung, WH Chung, LB Liou, CC Chu… - Proceedings of the …, 2005 - National Acad Sciences
Allopurinol, a commonly prescribed medication for gout and hyperuricemia, is a frequent
cause of severe cutaneous adverse reactions (SCAR), which include the drug …

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind …

HR Schumacher Jr, MA Becker… - Arthritis Care & …, 2008 - Wiley Online Library
Objective To compare the urate‐lowering efficacy and safety of febuxostat, allopurinol, and
placebo in a large group of subjects with hyperuricemia and gout, including persons with …

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol

LK Stamp, WJ Taylor, PB Jones… - Arthritis & …, 2012 - Wiley Online Library
Objective Allopurinol is the most commonly used urate‐lowering therapy in gout. Allopurinol
hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event. Dosing …

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

S Halevy, PD Ghislain, M Mockenhaupt… - Journal of the American …, 2008 - Elsevier
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
are rare severe cutaneous adverse reactions. OBJECTIVES: We sought to update …

Dietary flavonoids as xanthine oxidase inhibitors: Structure–affinity and structure–activity relationships

S Lin, G Zhang, Y Liao, J Pan… - Journal of agricultural and …, 2015 - ACS Publications
The flavonoid family has been reported to possess a high potential for inhibition of xanthine
oxidase (XO). This study concerned the structural aspects of inhibitory activities and binding …

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

Y Takano, K Hase-Aoki, H Horiuchi, L Zhao… - Life sciences, 2005 - Elsevier
The purine analogue, allopurinol, has been in clinical use for more than 30 years as an
inhibitor of xanthine oxidase (XO) in the treatment of hyperuricemia and gout. As …

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and …

WH Chung, WC Chang, SL Stocker, CG Juo… - Annals of the …, 2015 - ard.bmj.com
Objective Allopurinol, an antihyperuricaemic agent, is one of the common causes of life-
threatening severe cutaneous adverse reactions (SCAR), including drug rash with …

Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase

Y Chen, Z Zhao, Y Li, Y Yang, L Li, Y Jiang, C Lin… - Phytomedicine, 2021 - Elsevier
Background Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the
dominant causes of hyperuricemia. Baicalein (BAL) is widely distributed in dietary plants …